Acute Dystonia 
- "Long-lasting contraction or spasm of musculature 
           develops secondary to  the use of antipsychotic medication.
 
- Acute dystonia typically subsides 
              spontaneously within hours after onset.
 
 
              
                | Common Dystonias  | 
               
                
- Torticollis (lateral neck rotation)
 
- Retrocollis (neck extension)
 
- Limb torsion
 
- Forced jaw closing (trismus) or opening
 
- Tongue protrusion
 
- Opisthotonus (extension of head, neck, and paraspinal muscles in an 
                    arch)
 
- Oculogyric crisis (forceful eye deviation).
 
 
 | 
               
 
- Usually emerge within 0–7 days 
 
- Pathophysiology
             
- Abnormalities in dopamine–acetylcholine balance -
                 (cholinergic antagonists and dopaminergic agonists  improve the dystonia in many patients)
 
 
 
- Epidemiology
             
- 2 to 12% of patients -
                  conventional antipsychotic medication
 
 
 
- Risk factors include
             
- high-potency conventional antipsychotics, e.g. haloperidol
 
- Young age, male sex, and a prior dystonic
                  reaction.  
 
 
 
- Clinical features
             
- Abnormal positioning of the head and neck in 
                  relation to the body (e.g., retrocollis, torticollis)
 
- Spasms of the jaw muscles (trismus, gaping, 
                    grimacing)
 
- Impaired swallowing (dysphagia), speaking,
                 or breathing (laryngeal–pharyngeal spasm, 
                 dysphonia)
 
- Thickened or slurred speech due to hypertonic 
                 or enlarged tongue (dysarthria, macroglossia) 
                 tongue protrusion or tongue dysfunction
 
- Eyes deviated up, down, or sideward 
                 (oculogyric crisis)
 
- Abnormal positioning of the distal limbs or 
                  trunk 
 
 
 
- Treatment
             
- Standard treatment is anticholinergic agent- equivalent of 2 mg of benztropine or 50 mg of diphenhydramine/promethazine.
 
- In case of laryngeal or pharyngeal dystonias with 
                    airway compromise, repeated dosing of medication should 
                  occur at shorter intervals until resolution is achieved.
 
 
 
 
 | 
     
     Parkinsonism
      
       
- A condition characterized by Parkinsonian 
                signs or symptoms (resting tremor, muscle rigidity, and 
bradykinesia/akinesia) that develop in association with the use of an 
antipsychotic medication.
 
- Most commonly associated with use of Dopamine Receptor Antagonists.
 
- Pathophysiology
                
- Blockade of postsynaptic 
                  dopamine (D2 ) receptors in the corpus striatum.
 
 
 
- Epidemiology
             
- 5 to 90%, depending on the use of first-generation 
antipsychotics, high-potency FGAs and associated medical and 
neurological disorders. 
 
 
 
- Clinical features include:
             
- Parkinsonian tremor (i.e., a coarse, rhythmic, 
                 resting tremor with a frequency between 3 
                 and 6 cycles per second, affecting the limbs,
 
                  head, mouth, or tongue) 
- Parkinsonian muscular rigidity (i.e., cogwheel 
                    rigidity or continuous “lead-pipe” rigidity) 
 
- Akinesia (i.e., a decrease in spontaneous 
                 facial expressions, gestures, speech, or body 
                  movements) 
 
 
 
- Differential diagnosis include:
             
- Major depressive disorder 
 
- Catatonia
 
- Negative symptoms 
                  of schizophrenia
 
 
 
- Treatment
             
- Milder cases do not require treatment, reassurance that condition will improve as patient will tolerate the drug over time.
 
- Decrease the dose of antipsychotic to the lowest effective
 
                  dose for the patient. 
- Low dose anticholinergic - benztropine/trihexyphenidyl 
 
- Treat with  atypical 
                  antipsychotics.
 
 
 
 
 | 
     
    Akathisia (“inability to sit”) 
- Definition 
                : “A subjective feeling of restlessness and an  
intensely unpleasant need to move occurring secondary to antipsychotic  
treatment”. 
 
- Usually emerge with in 7–14 days of starting antipsychotics therapy. 
 
- Pathophysiology
          
- Excessive noradrenergic activity (the  efficacy of beta-adrenergic blockers in improving some cases of akathisia)
 
- Mesocortical dopaminergic neurons that  innervate the 
prefrontal cortex seem to be resistant to depolarization induced  by 
long-term antipsychotic treatment. 
 
 
 
- Epidemiology
          
- Occur in 20–75% of patients treated with  conventional agents. 
 
 
 
- Clinical features
          
- Subjective complaints of restlessness
 
- Fidgety movements or swinging of the  legs
 
-  Rocking from foot to foot while standing
 
-  Pacing to relieve restlessness
 
-  Inability to sit or stand for at least several  minutes 
 
 
 
- Differential Diagnosis
          
- Primary psychiatric disorders  presenting with 
agitation, such as depression, mania, anxiety, schizophrenia,  dementia,
 delirium, substance intoxication/withdrawal, and attention-defi  
cit/hyperactivity disorder.
 
- Restless legs syndrome (RLS) 
 
 
 
- Treatment
          
- Beta-blocker propranolol - often  considered first-line treatment 
 
- Benzodiazepines - clonazepam and Lorazepam 
 
- Anticholinergic agents – benztropine 
 
 
 
 
 | 
     
    Tardive Dyskinesia 
- Definition:
             
-  "A syndrome 
                 consisting of abnormal, involuntary, choreoathetoid 
movements typically involve the mouth, face, limbs, and trunk caused by 
long-term treatment with antipsychotic medication.
 
 
 
- Pathophysiology
                -  hypotheses 
                  
- Striatal dopamine receptor supersensitivity as
                    a compensatory reaction to prolonged dopamine receptor blockade.
 
- Damage to gamma-aminobutyric acid 
                  (GABA)-containing striatal neurons.
 
- Long-term antipsychotic use may 
                    produce toxic free radicals that damage striatal neurons 
                  and result in persistent TD.
 
- Reduced levels 
                    of brain-derived neurotrophic factor (BDNF) and elevated 
                  serum homocysteine.
 
 
 
- Epidemiology - (after starting antipsychotics)
             
- 5% after 1 year
 
-  18.5% after 4 years
 
-  40% after 8 years
 
 
 
- Clinical Features 
                
- Involuntary movements of the tongue, jaw, trunk, 
                    or extremities have developed in association with 
                  the use of neuroleptic medication.
 
- Choreiform movements (i.e., rapid, jerky, 
                    nonrepetitive)
 
- Athetoid movements (i.e., slow, sinuous, 
                    continual)
 
- Rhythmic movements (i.e., stereotypies)
 
 
 
- Differential Diagnosis
                
- Sydenham’s chorea
 
- Huntington’s disease 
 
- Conversion disorder and 
                  malingering
 
- Hyperthyroidism
 
 
 
- Complications
                
- Emotional distress
 
- Dental problems
 
- Respiratory alkalosis
 
 
 
- Treatment
                
- Atypical 
                  antipsychotics may improve the condition
 
- Clozapine 
                    may be effective in reducing TD in patients with existing 
                  TD 
 
- Vitamin 
                  E (alpha-tocopherol) has some efficiency
 
- Abnormal Involuntary Movement Scale (AIMS) may be used to monitor progress of the treatment. 
 
 
 
 
 | 
     
    
Scales & Instruments  
Simpson-Angus Rating Scale for Extrapyramidal Side Effects  
- The Simpson-Angus scale was developed to monitor the effects of antipsychotic drugs. 
 
- It has 10 items, each of which is rated on an item-specific, five-point severity scale ranging from 0 to 4. 
 
- Scores are reported as the mean on all 10 items, with 0.3 considered the upper limit of normal.
 
-  It is  focused on parkinsonian symptoms, -rigidity,includes one akathisia item.
 
-  It can be administered by trained lay raters.
 
- Good psychometric properties have been reported.
 
 
Abnormal Involuntary Movement Scale (AIMS) 
- developed to measure dyskinetic symptoms in patients taking antipsychotic drugs. 
 
-  12 items,  on  five-point severity scale ranging from 0 to 4. 
 
- Total scores are not generally reported. Instead, changes in global severity and individual areas can be monitored over time. 
 
- Ten items cover the movements themselves, divided into 
sections rating global severity and those related to specific body 
regions; two items concern dental factors that can complicate the 
diagnosis of dyskinesia.
 
-  In the presence of extended neuroleptic exposure and the 
absence of other conditions causing dyskinesia, mild dyskinetic 
movements in two areas or moderate movements in one area suggest a 
diagnosis of tardive dyskinesia. 
 
- The scale can be administered by trained raters.
 
-  It can be completed in under 10 minutes. 
 
- Good psychometric properties have been reported.
 
 
 | 
     
    
References 
- 
             
Miyamoto S, Merrill DB, Lieberman JA, Fleischacker WW, Marder SR. Antipsychotic Drugs. In Psychiatry,
 Third Edition. Edrs. Allan Tasman, Jerald Kay, Jeffrey A. Lieberman, 
Michael B. First and Mario Maj.John Wiley & Sons, Ltd, 2008. 
 
- Daniel DG, Igan MF, Wolf SS.  Neuropsychiatric Aspects of Movement Disorders. In Comprehensive 
                Textbook of Psychiatry , Vol 7 , Kaplan HI and Saddock BJ (eds). Williams & Wilkins , Baltimore, MD, USA .
 
 
 | 
 
0 comments:
Post a Comment